Cervical Cancer

>

Latest News

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors
Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

November 13th 2024

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

Pembrolizumab Combo Shows Promising Results in High-Risk Cervical Cancer
Pembrolizumab Combo Shows Promising Results in High-Risk Cervical Cancer

November 4th 2024

KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer

September 14th 2024

Pembrolizumab Plus CCRT Scores in East Asian Subgroup With Cervical Cancer
Pembrolizumab Plus CCRT Scores in East Asian Subgroup With Cervical Cancer

September 9th 2024

Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer

July 22nd 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

More News

Is PD-L1 an Appropriate Biomarker in Cervical Cancer?

Is PD-L1 an Appropriate Biomarker in Cervical Cancer?

Tony Berberabe, MPH
August 23rd 2022

Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.

Read More

Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer

Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer

Tony Berberabe, MPH
June 6th 2022

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

Read More

Behind the FDA Approval: Tisotumab Vedotin for Metastatic Cervical Cancer

Behind the FDA Approval: Tisotumab Vedotin for Metastatic Cervical Cancer

Nichole Tucker
February 2nd 2022

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.

Read More

<12